A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Running, not enrolling · Phase 1

Conditions studied: Relapsed/Refractory Multiple Myeloma

In brief

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Etentamig co-administered with Pd, Rd, or Dd, will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. This study will include a dose escalation phase to determine the best dose of etentamig, followed by a dose expansion phase to confirm the dose. Approximately 320 adult participants with R/R MM will be enrolled in the study in approximately 48 sites worldwide. Participants will receive intravenous (IV) etentamig co-administered with oral/IV Pd, oral/IV Rd, or oral/IV/subcutaneous (SC) Dd in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Key facts

Study ID

NCT05259839

Run by

AbbVie

People needed

283

Starts

2022-10-20

Expected to finish

2033-09-01

Last updated by the study team

2025-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eastern Cooperative Oncology Group (ECOG) performance of <= 2.
• Must have confirmed diagnosis of Relapsed/Refractory (R/R) Multiple Myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the International Myeloma Working Group (IMWG) criteria.
• Must have measurable disease as determined by central lab as outlined in the protocol.
• Must be naïve to treatment with Etentamig.
• Must have never received BCMA-targeted therapy. Participants who have received targeted therapy against non-BCMA targets will not be excluded.
• Arms A, B and C: Participant has received at least 3 prior lines of MM treatment.
• Arm E: Participant has received 1-3 prior lines of MM treatment.

You may not qualify if…

• Received a peripheral autologous stem cell transplant (SCT) within 12 weeks, or an allogeneic SCT within 1 year of the first dose of study treatment.
• Unresolved adverse event (AE)s >= Grade 2 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) from prior anticancer therapy.
• Has any of the following conditions:
• Nonsecretory Multiple Myeloma (MM).
• Active Plasma cell leukemia i.e., either 20% of peripheral white blood cells or > 2.0 × 10\^9L circulating plasma cells by standard differential.
• Waldenstrom's macroglobulinemia.
• Light chain amyloidosis.
• Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes (POEMS) syndrome.
• Major surgery within 4 weeks prior to first dose or planned study participation.
• Acute infections within 14 days prior to first dose of study requiring therapy (antibiotic, antifungal or antiviral).
• Uncontrolled diabetes or hypertension within 14 days prior to first dose.
• Peripheral neuropathy >= Grade 3 or >= Grade 2 with pain within 2 weeks prior to first dose.

Where it is running

• University of Arkansas for Medical Sciences /ID# 243096 — Little Rock, Arkansas, United States
• Sylvester Comprehensive Cancer Center /ID# 243673 — Miami, Florida, United States
• Moffitt Cancer Center /ID# 243437 — Tampa, Florida, United States
• University of Maryland, Baltimore /ID# 243679 — Baltimore, Maryland, United States
• Dana-Farber Cancer Institute /ID# 249529 — Boston, Massachusetts, United States
• University of Massachusetts - Worcester /ID# 243977 — Worcester, Massachusetts, United States
• University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 243438 — Ann Arbor, Michigan, United States
• The Valley Hospital /ID# 243829 — Paramus, New Jersey, United States
• Rutenberg Cancer Center /ID# 244647 — New York, New York, United States
• Memorial Sloan Kettering Cancer Center /ID# 244656 — New York, New York, United States
• Atrium Health Levine Cancer Institute /ID# 242851 — Charlotte, North Carolina, United States
• University of Texas Southwestern Medical Center /ID# 243273 — Dallas, Texas, United States
• Huntsman Cancer Institute /ID# 242872 — Salt Lake City, Utah, United States
• University of Washington /ID# 243172 — Seattle, Washington, United States
• Froedtert Memorial Lutheran Hospital /ID# 242654 — Milwaukee, Wisconsin, United States
• St George Hospital /ID# 243740 — Kogarah, New South Wales, Australia
• Calvary Mater Newcastle /ID# 243730 — Waratah, New South Wales, Australia
• Monash Health - Monash Medical Centre /ID# 244403 — Clayton, Victoria, Australia
• St Vincent's Hospital Melbourne /ID# 256879 — Fitzroy Melbourne, Victoria, Australia
• Peter MacCallum Cancer Ctr /ID# 256880 — Melbourne, Victoria, Australia
• Epworth Healthcare /ID# 243734 — Richmond, Victoria, Australia
• Fiona Stanley Hospital /ID# 244753 — Murdoch, Western Australia, Australia
• Universitaetsklinikum Tuebingen /ID# 242815 — Tübingen, Baden-Wurttemberg, Germany
• Universitaetsklinikum Wuerzburg /ID# 242826 — Würzburg, Bavaria, Germany
• Universitaetsklinikum Essen /ID# 242819 — Essen, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.